The combination of PI3K inhibitors with either HER2 or MEK inhibitors resulted in decreased proliferation, enhanced cell death and superior anti-tumor activity in vivo compared with single agent PI3K inhibitors. The gene discussed is ERBB2; the disease is neoplasm.